Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ALTA BIOPHARMA PARTNERS II LP
   2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [CORT] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
ONE EMBARCADERO CENTER, SUITE 3700		 3. Date of Earliest Transaction (Month/Day/Year)
03/25/2008
(Street)

SAN FRANCISCO, CA 94111		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/25/2008   P   1,045,921 A $ 2.77 5,043,299 I By Fund (1) (2)
Common Stock 03/25/2008   P   13,214 A $ 2.77 166,491 I By Fund (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant $ 2.77 03/25/2008   P   522,960   03/25/2008 03/25/2015 Common 522,960 (1) $ 0.125 522,960 I By Fund (1) (2)
Warrant $ 2.77 03/25/2008   P   6,607   03/25/2008 03/25/2015 Common 6,607 $ 0.125 6,607 I By Fund (2) (3)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ALTA BIOPHARMA PARTNERS II LP
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    
ALTA CALIFORNIA MANAGEMENT PARTNERS II LLC
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    
ALTA EMBARCADERO PARTNERS II LLC
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    
DELEAGE JEAN
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    
CHAMPSI FARAH
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    
ALTA PARTNERS II INC
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111		     X    

Signatures

 Alta BioPharma Partners II, L.P. By: Alta BioPharma Management II, LLC By: Alix Marduel, its Managing Director /s/Alix Marduel   03/26/2008
**Signature of Reporting Person Date
 Alix Marduel, Managing Director   03/26/2008
**Signature of Reporting Person Date
 Alix Marduel, Manager   03/26/2008
**Signature of Reporting Person Date
 Jean Deleage   03/26/2008
**Signature of Reporting Person Date
 Farah Champsi   03/26/2008
**Signature of Reporting Person Date
 Jean Deleage, its President   03/26/2008
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These securities are held by Alta BioPharma Partners II, L.P. ("ABPII").
(2) Alta Partners II, Inc. ("APII") provides investment advisory services to ABPII and Alta Embarcadero BioPharma Partners II, LLC ("AEBPII" and, along with ABPII, the "Funds"). Jean Deleage, Alix Marduel and Farah Champsi (collectively, the "Principals") are managing directors of Alta BioPharma Management II, LLC ("ABMII"), which is the general partner of ABPII, and the managers of AEBPII. Ms. Marduel is a director of the Issuer and files separate Section 16 reports. The Principals may be deemed to share voting and investment power over the shares held by the Funds. Each of the Reporting Persons disclaims beneficial ownership of all such shares held by the Funds, except to the extent of his, her or its proportionate pecuniary interest therein.
(3) These securities are held by AEBPII.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.